María José Gallardo-NelsonMarcos CrucesYolanda M. GómezConstanza FuenzalidaConstanza FuenzalidaJaviera SilvaLaura Aravena-TraipiEduardo NuñezAracelly Gaete-ÁngelElizabeth Rivas-YañezAlexis M. KalergisRicardo Soto-RifoFernando Valiente-EcheverriaGALLARDO NELSON MARIA JOSE2025-05-222025-05-222024Li, Y., Zhang, X., & Chen, H. (2024). Advances in immune modulation for tumor therapy: Focus on emerging checkpoints. Frontiers in Immunology, 15, 1427501. https://doi.org/10.3389/fimmu.2024.1427501https://hdl.handle.net/20.500.12740/22445This longitudinal observational study evaluated the humoral immune response to SARS-CoV-2 vaccines in adults with immune-mediated rheumatic diseases (IMRDs) compared to healthy controls, 1–20 weeks after receiving a fourth vaccine dose. Neutralizing antibody titers against the Wuhan and Omicron variants were measured in 341 individuals (218 IMRD patients and 123 healthy controls). Results showed significantly lower antibody responses in IMRD patients, particularly against Omicron (p = 0.0015), and further decline when sample collection occurred more than 35 days post-vaccination. Vaccine type, dosage, timing, and immunosuppressive treatment were all influential factors. These findings underscore the variability in vaccine-induced immunity among IMRD patients.text/htmlSARS-CoV-2COVID-19booster vaccinationimmune-mediated rheumatic diseasesimmunogenicityneutralizing antibodiesother10.3389/fimmu.2024.1427501